504059650 10/20/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4106316

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NOVARTIS VACCINES AND DIAGNOSTICS SRL	10/20/2016

RECEIVING PARTY DATA

Name:	GLAXOSMITHKLINE BIOLOGICALS SA	
Street Address:	RUE DE l'INSTITUT 89	
City:	RIXENSART	
State/Country:	BELGIUM	
Postal Code:	1330	

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	14224031	

CORRESPONDENCE DATA

Fax Number: (610)270-5090

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6102706812

Email: us_cipkop@gsk.com

Correspondent Name: GLAXOSMITHKLINE

Address Line 1: 709 SWEDELAND ROAD

Address Line 2: UW2220

Address Line 4: KING OF PRUSSIA, PENNSYLVANIA 19406

ATTORNEY DOCKET NUMBER:	VN51619
NAME OF SUBMITTER:	CARLY MORROW
SIGNATURE:	/Carly Morrow/
DATE SIGNED:	10/20/2016

Total Attachments: 2

source=VN51619 GEN Confirmatory Assignment#page1.tif source=VN51619 GEN Confirmatory Assignment#page2.tif

PATENT 504059650 REEL: 040077 FRAME: 0642

CONFIRMATORY ASSIGNMENT

WE, GSK VACCINES S R L (formerly known as NOVARTIS VACCINES AND DIAGNOSTICS S R L) a company incorporated under the laws of Italy, having its registered office at Via Fiorentina 1, 53100, Siena, Italy, and Novartis AG a company limited by shares duly incorporated in Switzerland and whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland do hereby declare that we are or were the sole owner of the following patents/applications listed in the attached Schedule 1, entitled Meningococcus Adhesions NADA, APP and ORF 40

And in accordance with the Patent Assignment Agreement dated 26 February 2015 between Novartis Vaccines and Diagnostics S r I, Novartis Pharma AG and Novartis AG, NOVARTIS VACCINES AND DIAGNOSTICS S R L has assigned and GSK VACCINES S R L hereby assigns the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/these application(s) are filed to Novartis AG

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between NOVARTIS AG and GLAXOSMITHKLINE BIOLOGICALS SA for good and valuable consideration, the receipt of which is hereby acknowledged, we NOVARTIS AG have assigned and hereby assign the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/these application(s) are filed to GLAXOSMITHKLINE BIOLOGICALS SA of Rue de l'Institut 89, 1330 Rixensart, Belgium

NOVARTIS VACCINES AND DIAGNOSTICS S R L has changed its name, as of 1 September 2015, into the new name "GLAXOSMITHKLINE VACCINES S R L " or in abbreviated form "GSK VACCINES S R L "

Dated this 20 October 2016

Signed for and on behalf of GSK VACCINES S R L

Lorrane B Ling
Authorised Signatory on behalf of GSK VACCINES S R L

Signed for and on behalf of NOVARTIS AG

William R Majarian

Authorized Signatory on behalf of

NOVARTIS AG

Theodore R Furman

Authorized Signatory on behalf of

NOVARTIS AG

Signed for and on behalf of GLAXOSMITHKLINE BIOLOGICALS SA

Edward Ry Cimmi

Authorized of flicial on behalf of GLAXOSMITHKLINE BIOLOGICALS SA

PATENT REEL: 040077 FRAME: 0643

Country	Application Date	Schedule 1 Application Number	Grant Date	Patent Number
European Patent Convention	26-Jul-02	10005685 2		
Japan	16-Feb-09	2009-033304	13 - Jan-12	4902678
United States	24-Mar-14	14/224031	02-Feb-16	9249197

PATENT REEL: 040077 FRAME: 0644

RECORDED: 10/20/2016